Seroprevalence of novel coronavirus disease (COVID-19) in Kobe, Japan
Seroprevalence of novel coronavirus disease (COVID-19) in Kobe, Japan
复制标题
日本神户市新型冠状病毒病（COVID-19）的血清流行率
DOI：
--
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Y. Kihara
中科院分区：
文献类型：
--
作者：
A. Doi;K. Iwata;H. Kuroda;Toshikazu Hasuike;Seiko Nasu;Aya Kanda;Tomomi Nagao;H. Nishioka;K. Tomii;T. Morimoto;Y. Kihara
由SARS-CoV-2引起的冠状病毒病2019(新冠肺炎)大流行已经影响到地球上的许多人和我们的社会。众所周知，在发达国家中，日本的感染人数和死亡人数相对较少。然而，新冠肺炎在日本的准确流行情况仍不得而知。因此，我们开展了SARS-CoV-2感染的横断面研究。我们对2020年3月31日至4月7日门诊就诊的1000例患者进行了SARS-CoV-2抗体的横断面血清学检测，按年龄和性别分层。在1000份血清样本中，有33份抗体阳性(3.3%，95%CI：2.3-4.6%)。通过将这一数字应用于神户市(人口：1,518,870)的普查，估计免疫球蛋白阳性人数为50,123人(95%可信区间：34,934-69,868)。年龄和性别调整后的阳性患病率为2.7%(95%可信区间：1.8-3.9%)，估计抗体阳性人数为40,999人(95%可信区间：27,333-59,221)。这一数字是神户市PCR检测确诊病例的396至858倍。我们的横断面血清学研究表明，日本神户SARS-CoV-2感染血清阳性的人数远远多于PCR检测确诊病例。
Coronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has been affecting many people on earth and our society. Japan is known to have relatively less number of infections as well as deaths among developed nations. However, accurate prevalence of COVID-19 in Japan remains unknown. Therefore, we conducted a cross-sectional study to estimate seroprevalence of SARS-CoV-2 infection.We conducted a cross-sectional serologic testing for SARS-CoV-2 antibody using 1,000 samples from patients at outpatient settings who visited the clinic from March 31 to April 7, 2020, stratified by the decade of age and sex.There were 33 positive IgG among 1,000 serum samples (3.3%, 95%CI: 2.3-4.6%). By applying this figure to the census of Kobe City (population: 1,518,870), it is estimated that the number of people with positive IgG be 50,123 (95%CI: 34,934-69,868). Age and sex adjusted prevalence of positivity was calculated 2.7% (95%CI: 1.8-3.9%), and the estimated number of people with positive IgG was 40,999 (95%CI: 27,333-59,221). These numbers were 396 to 858 fold more than confirmed cases with PCR testing in Kobe City.Our cross-sectional serological study suggests that the number of people with seropositive for SARS-CoV-2 infection in Kobe, Japan is far more than the confirmed cases by PCR testing.